As somatic mutations could explain some molecular mechanisms involved in tumour progress, we classified patients in TCGA glioma cohort into two groups according to the median expression of SLC12A5 and compared the frequency of mutations between high‐expression group and low‐expression group. This evidence concerns the gene SLC12A5 and glioma.